Update

Update in thyroidology

E. Chester Ridgway, Yaron Tomer, Sandra M. McLachlan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The human and mouse genome databases have provided powerful tools to probe many unanswered questions in thyroidology. Mechanistic knowledge regarding thyroid development, thyroid gland regulation by hypothalamic-pituitary function, thyroid hormone transport and action, thyroid autoimmunity and genetics, and thyroid oncogenesis have expanded enormously using molecular genetics. This basic information is providing the foundation for new clinical approaches to the diagnosis and therapy of thyroid disorders. For example, old dogma regarding the transport of thyroid hormones into cells being mediated by passive diffusion is being discarded as knowledge of new small molecule transporters has been discovered and related to human disease. The genetic basis for autoimmune thyroid disease is being unraveled by discovery of genetic variations associated with risk for autoimmune disease and important molecules in the disorder's pathogenesis. The translation of basic molecular genetic knowledge into clinical care is no better illustrated than in thyroid cancer, in which genetic mutations in molecules of the MAPK pathway have been shown to account for more than 70% of papillary thyroid cancers. Furthermore, certain mutations may predict clinical outcomes, such as cancer recurrence. The new molecular understanding of thyroid cancer causation isnowopening a new therapeutic frontier as drugs are developed that modulate the MAPK pathway.

Original languageEnglish (US)
Pages (from-to)3755-3761
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume92
Issue number10
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Thyroid Gland
Thyroid Hormones
Molecules
Thyroid Neoplasms
Autoimmune Diseases
Molecular Biology
Genes
Mutation
Thyroid Diseases
Human Genome
Autoimmunity
Causality
Carcinogenesis
Pharmaceutical Preparations
Databases
Recurrence
Therapeutics
Genetics
Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Update : Update in thyroidology. / Ridgway, E. Chester; Tomer, Yaron; McLachlan, Sandra M.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 92, No. 10, 10.2007, p. 3755-3761.

Research output: Contribution to journalArticle

Ridgway, E. Chester ; Tomer, Yaron ; McLachlan, Sandra M. / Update : Update in thyroidology. In: Journal of Clinical Endocrinology and Metabolism. 2007 ; Vol. 92, No. 10. pp. 3755-3761.
@article{e66abbdb844a4078b03f2375f176a5ae,
title = "Update: Update in thyroidology",
abstract = "The human and mouse genome databases have provided powerful tools to probe many unanswered questions in thyroidology. Mechanistic knowledge regarding thyroid development, thyroid gland regulation by hypothalamic-pituitary function, thyroid hormone transport and action, thyroid autoimmunity and genetics, and thyroid oncogenesis have expanded enormously using molecular genetics. This basic information is providing the foundation for new clinical approaches to the diagnosis and therapy of thyroid disorders. For example, old dogma regarding the transport of thyroid hormones into cells being mediated by passive diffusion is being discarded as knowledge of new small molecule transporters has been discovered and related to human disease. The genetic basis for autoimmune thyroid disease is being unraveled by discovery of genetic variations associated with risk for autoimmune disease and important molecules in the disorder's pathogenesis. The translation of basic molecular genetic knowledge into clinical care is no better illustrated than in thyroid cancer, in which genetic mutations in molecules of the MAPK pathway have been shown to account for more than 70{\%} of papillary thyroid cancers. Furthermore, certain mutations may predict clinical outcomes, such as cancer recurrence. The new molecular understanding of thyroid cancer causation isnowopening a new therapeutic frontier as drugs are developed that modulate the MAPK pathway.",
author = "Ridgway, {E. Chester} and Yaron Tomer and McLachlan, {Sandra M.}",
year = "2007",
month = "10",
doi = "10.1210/jc.2007-1855",
language = "English (US)",
volume = "92",
pages = "3755--3761",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Update

T2 - Update in thyroidology

AU - Ridgway, E. Chester

AU - Tomer, Yaron

AU - McLachlan, Sandra M.

PY - 2007/10

Y1 - 2007/10

N2 - The human and mouse genome databases have provided powerful tools to probe many unanswered questions in thyroidology. Mechanistic knowledge regarding thyroid development, thyroid gland regulation by hypothalamic-pituitary function, thyroid hormone transport and action, thyroid autoimmunity and genetics, and thyroid oncogenesis have expanded enormously using molecular genetics. This basic information is providing the foundation for new clinical approaches to the diagnosis and therapy of thyroid disorders. For example, old dogma regarding the transport of thyroid hormones into cells being mediated by passive diffusion is being discarded as knowledge of new small molecule transporters has been discovered and related to human disease. The genetic basis for autoimmune thyroid disease is being unraveled by discovery of genetic variations associated with risk for autoimmune disease and important molecules in the disorder's pathogenesis. The translation of basic molecular genetic knowledge into clinical care is no better illustrated than in thyroid cancer, in which genetic mutations in molecules of the MAPK pathway have been shown to account for more than 70% of papillary thyroid cancers. Furthermore, certain mutations may predict clinical outcomes, such as cancer recurrence. The new molecular understanding of thyroid cancer causation isnowopening a new therapeutic frontier as drugs are developed that modulate the MAPK pathway.

AB - The human and mouse genome databases have provided powerful tools to probe many unanswered questions in thyroidology. Mechanistic knowledge regarding thyroid development, thyroid gland regulation by hypothalamic-pituitary function, thyroid hormone transport and action, thyroid autoimmunity and genetics, and thyroid oncogenesis have expanded enormously using molecular genetics. This basic information is providing the foundation for new clinical approaches to the diagnosis and therapy of thyroid disorders. For example, old dogma regarding the transport of thyroid hormones into cells being mediated by passive diffusion is being discarded as knowledge of new small molecule transporters has been discovered and related to human disease. The genetic basis for autoimmune thyroid disease is being unraveled by discovery of genetic variations associated with risk for autoimmune disease and important molecules in the disorder's pathogenesis. The translation of basic molecular genetic knowledge into clinical care is no better illustrated than in thyroid cancer, in which genetic mutations in molecules of the MAPK pathway have been shown to account for more than 70% of papillary thyroid cancers. Furthermore, certain mutations may predict clinical outcomes, such as cancer recurrence. The new molecular understanding of thyroid cancer causation isnowopening a new therapeutic frontier as drugs are developed that modulate the MAPK pathway.

UR - http://www.scopus.com/inward/record.url?scp=35348937628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348937628&partnerID=8YFLogxK

U2 - 10.1210/jc.2007-1855

DO - 10.1210/jc.2007-1855

M3 - Article

VL - 92

SP - 3755

EP - 3761

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -